Schedule 13G: 4.37M Shares (5.51%) Reported in BridgeBio Oncology

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics, Inc. has a Schedule 13G reporting that BC Global Opportunities IX LP and affiliated reporting persons beneficially own 4,365,747 shares of the issuer's common stock, representing 5.51% of the class. The filing shows no sole voting or dispositive power by any reporting person; all voting and dispositive power is reported as shared. Reported reporting persons include BC Global Opportunities IX LP, BC General Partner, LP, BC Capital Management Limited and an individual, Tan Kuangming. The filing states the shares were not acquired to change or influence control of the issuer and discloses British Virgin Islands and Hong Kong citizenship/places of organization for the entities and individual involved.

Positive

• Disclosure of beneficial ownership above 5% (4,365,747 shares, 5.51%) provides transparency to the market
• Reporting persons certify passive intent, stating the shares were not acquired to change or influence control

Negative

• None.

Insights

Securities Analyst

TL;DR: A coordinated holder group disclosed beneficial ownership of 5.51%, with only shared voting/dispositive power and a certification of no intent to influence control.

This Schedule 13G reveals a non-active investor position above the 5% reporting threshold. The position is held through an investment vehicle (BC Global Opportunities IX LP) and related entities, with identical share counts and shared voting/dispositive rights across all reporting persons. The certification that the holdings are not for control purposes and the selection of Schedule 13G treatment suggest passive intent under the filer’s stated facts. For investors, the disclosure clarifies ownership concentration but shows no unilateral control or activist signal in the filing itself.

Corporate Governance Expert

TL;DR: Ownership structure is centralized in a single economic owner via affiliated entities, but formal control remains shared.

The filing documents a single economic position distributed across related legal entities and an individual, with shared voting and dispositive power reported. That structure is common for fund investments and places emphasis on governance transparency: beneficial ownership exceeds 5% so public disclosure occurred, yet the absence of sole voting power indicates no direct control asserted. The certification limits regulatory concern about an attempted change of control, though further filings would be required if the holder’s intent changes.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

BridgeBio Oncology Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

107924102

(CUSIP Number)

09/04/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 107924102

1

Names of Reporting Persons

BC Global Opportunities IX LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

VIRGIN ISLANDS, BRITISH

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,365,747.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,365,747.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,365,747.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.5 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No. 107924102

1

Names of Reporting Persons

BC General Partner, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

VIRGIN ISLANDS, BRITISH

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,365,747.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,365,747.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,365,747.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.5 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: Comprise of shares of Common Stock held by BC Global Opportunities IX LP, of which BC General Partner, LP is the general partner.

SCHEDULE 13G

CUSIP No. 107924102

1

Names of Reporting Persons

BC Capital Management Limited

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

VIRGIN ISLANDS, BRITISH

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,365,747.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,365,747.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,365,747.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.5 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: Comprised of shares of Common Stock held by BC General Partner, LP, of which BC Capital Management Limited is the general partner.

SCHEDULE 13G

CUSIP No. 107924102

1

Names of Reporting Persons

Tan Kuangming

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

VIRGIN ISLANDS, BRITISH

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,365,747.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,365,747.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,365,747.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.5 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: Comprised of shares of Common Stock held by BC Global Opportunities IX LP.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: BridgeBio Oncology Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 256 E. GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO, CALIFORNIA, 94080
Item 2.
(a)	Name of person filing: BC Global Opportunities IX LP, BC General Partner, LP, BC Capital Management Limited, Tan Kuangming
(b)	Address or principal business office or, if none, residence: BC Global Opportunities IX LP, BC General Partner, LP, BC Capital Management Limited, Vistra (BVI) Limited of Vistra Corporate Services Centre, Wickhams Cay Il, Road Town, Tortola, VG1110, British Virgin Islands Tan Kuangming Room 1202-07, 12/F, Nan Fung Tower, No. 88 Connaught Road Central, Central, Hong Kong
(c)	Citizenship: C Global Opportunities IX LP, BC General Partner, LP, BC Capital Management Limited, Citizenship: British Virgin Islands Tan Kuangming, Citizenship: Hong Kong
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 107924102
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: BC Global Opportunities IX LP - 4,365,747 shares BC General Partner, LP - 4,365,747 shares BC Capital Management Limited - 4,365,747 shares Tan Kuangming - 4,365,747 shares
(b)	Percent of class: BC Global Opportunities IX LP - 5.51% BC General Partner, LP - 5.51% BC Capital Management Limited - 5.51% Tan Kuangming - 5.51%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: All Reporting Persons - 0
	(ii) Shared power to vote or to direct the vote: BC Global Opportunities IX LP - 4,365,747 BC General Partner, LP - 4,365,747 BC Capital Management Limited - 4,365,747 Tan Kuangming - 4,365,747
	(iii) Sole power to dispose or to direct the disposition of: All Reporting Persons - 0
	(iv) Shared power to dispose or to direct the disposition of: BC Global Opportunities IX LP - 4,365,747 BC General Partner, LP - 4,365,747 BC Capital Management Limited - 4,365,747 Tan Kuangming - 4,365,747
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BC Global Opportunities IX LP

Signature:	Freeman Szeto
Name/Title:	Operation Manager
Date:	09/04/2025

BC General Partner, LP

Signature:	Freeman Szeto
Name/Title:	Operation Manager
Date:	09/04/2025

BC Capital Management Limited

Signature:	Freeman Szeto
Name/Title:	Operation Manager
Date:	09/04/2025

Tan Kuangming

Signature:	Tan Kuangming
Name/Title:	Director
Date:	09/04/2025

FAQ

What stake did BC Global Opportunities IX LP report in BridgeBio Oncology Therapeutics?

The filing reports 4,365,747 shares, representing 5.51% of the class.

Do any reporting persons have sole voting or dispositive power over the shares?

No. The filing shows 0 shares with sole voting or dispositive power; all 4,365,747 shares are reported as shared voting and shared dispositive power.

Which entities and individuals filed the Schedule 13G?

The filers are BC Global Opportunities IX LP, BC General Partner, LP, BC Capital Management Limited, and Tan Kuangming.

What assertion did the filers make about their intent regarding control of the issuer?

The filers certified that, to the best of their knowledge and belief, the securities were not acquired and are not held to change or influence the control of the issuer.

Where are the reporting entities and individual organized or resident?

The entities are organized in the British Virgin Islands and the individual, Tan Kuangming, is a citizen of Hong Kong.